Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy

M Yalaz1, S Aydogdu, F Ozgenc

  • 1Neonatology Division, Department of Pediatrics, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.

Minerva Pediatrica
|December 17, 2003
PubMed

Normal fertility is sustained by progress in the medical therapy of Wilson's disease; however, pregnancy complications are encountered more frequently. The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years. She was admitted with unplanned pregnancy at the 16th gestational week. The dose of D-penicillamine could be reduced to 600 mg/d related to the underlying disease. Pregnancy ended with premature labor and delivery at the 29-30th weeks. The baby experienced type I respiratory distress and was treated by surfactant and mechanical ventilation. Neutropenia and leucopenia were documented at 6th postnatal hours. The baby showed neutropenia and leucopenia for 5 days and resolving without any further therapy. Intrauterine D-penicillamine was suspected to cause transient neonatal myelosuppression.